Patent intelligence · CN
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
Patent details — CN 117186084
- Jurisdiction
- CN
- Status
- granted
- Grant date
- Dec 8, 2023
- Expiration
- Dec 3, 2043
- Applicant
- BAYER HEALTHCARE AG
- CPC classes
- A61K 31/ 4439 A I, A61K/314439, A61K/4506, A61K/90014
Quick answer
CN 117186084 (Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus) is held by BAYER HEALTHCARE AG. Status: granted. Granted Dec 8, 2023. Expires Dec 3, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER HEALTHCARE AG
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4439 A I, A61K/314439, A61K/4506, A61K/90014, A61P 31/ 22 A I, A61P/3122
More from BAYER HEALTHCARE AG
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 117186084?
CN 117186084 (Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus) is held by BAYER HEALTHCARE AG. Status: granted. Granted Dec 8, 2023. Expires Dec 3, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CN 117186084?
BAYER HEALTHCARE AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does CN 117186084 expire?
Our index shows an expiration date of Dec 3, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.